Liraglutide Peptide CAS 204656-20-2

Liraglutide peptide is mainly used to treat type II diabetes. In addition, the study also found that it has potential therapeutic effects in other areas, as follows:

1. Therapeutic effect on diffuse alveolar hemorrhage in lupus mice: Liraglutide peptide preventive treatment can significantly reduce the degree of pulmonary hemorrhage in lupus DAH mice. By measuring lung wet weight, it was found that it was significantly lighter in the treated mouse lung tissue; The evaluation of the degree of gross pathological bleeding in lung tissue showed that the incidence rate of pulmonary hemorrhage in mice treated with it was significantly reduced; HE and Prussian blue staining analysis of pathological changes in lung tissue revealed a significant decrease in red blood cells and hemosiderin containing macrophages in the lung tissue of mice treated with it; ELISA detection found no significant change in the serum total IgM level of the mice treated with it, while the serum total IgG level was significantly lower

2. Effects on alcohol addicted mice: Liraglutide peptide can act on different regions of the reward loop in mice, regulating synaptic plasticity and neuroinflammation to alleviate abnormal behavior in alcohol addicted mice.The experimental results showed that compared with the alcohol group,the alcohol consumption and preference of mice in the alcohol+Liraglutide peptide group were reduced,and their learning ability was improved.At the same time, the expression levels of GFAP, Iba1, TNF α, and GFAP in mPFC were reduced by 2.